TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35259629

Group type: EXPERIMENTAL
Intervention: During lockdown (March 1 to May 11, 2020)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: During lockdown
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Waiting neoadjuvant chemotherapy in resectable tumours during lockdown
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Use of mFOLFIRINOX preoperative chemotherapy regimen during lockdown
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: After lockdown
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 833
Study: 35260030

Group type: EXPERIMENTAL
Intervention: Exposure based cognitive behavioral therapy (ECBT)
Number of subjects: 129
Study: 35260178

Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device (SonoCloud-1) with 1-MHz frequency, used in combination with intravenous infusion of microbubbles, administered over 3.5 months with seven ultrasound sessions (twice per month).
Number of subjects: 10
Study: 35260308

Group type: EXPERIMENTAL
Intervention: Mild malnutrition (n=21,092)
Number of subjects: 46485

Group type: EXPERIMENTAL
Intervention: Moderate malnutrition (n=5,286)
Number of subjects: 46485

Group type: EXPERIMENTAL
Intervention: Severe malnutrition (n=327)
Number of subjects: 46485

Group type: COMPARATOR
Intervention: Normal nutritional status (control group)
Number of subjects: 46485
Study: 35260313

Group type: EXPERIMENTAL
Intervention: Primary cardiovascular prevention program
Number of subjects: 1646
Study: 35260458

Group type: EXPERIMENTAL
Intervention: VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) two-dose vaccine regimen, doses given 56 days apart.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Delayed second dose of VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) vaccine.
Number of subjects: 1500
Study: 35260879

Group type: EXPERIMENTAL
Intervention: ABBV-085 antibody-drug conjugate (ADC)
Number of subjects: 0
Study: 35260913

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg on days 1 and 15, Irinotecan 125 mg/m²
Number of subjects: 26

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study: 35260962

Group type: EXPERIMENTAL
Intervention: Induced Hypertension (iHTN) via norepinephrine infusion in 20-mm Hg increments
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Immediate induction of hypertension with higher pressure targets
Number of subjects: 325

Group type: COMPARATOR
Intervention: Incremental approach to induced hypertension
Number of subjects: 325
Study: 35261130

Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) 0-1
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) 2-3
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) in patients with renal insufficiency
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) in patients with refractory ascites
Number of subjects: 144
Study: 35261265

Group type: EXPERIMENTAL
Intervention: Patients with SMI
Number of subjects: 591257

Group type: COMPARATOR
Intervention: Patients without SMI
Number of subjects: 591257
Study: 35261959

Group type: EXPERIMENTAL
Intervention: Flaxseed dietary intervention
Number of subjects: 100
Study: 35262412

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35262504

Group type: EXPERIMENTAL
Intervention: Online instant messaging peer support group with trained peer counselors on top of standard care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 35262780

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg intravenously every 2 weeks
Number of subjects: 21
Study: 35262794

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (DLCO) at 3, 6, and 12 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Chest CT scans at 3 and 12 months
Number of subjects: 85
Study: 35262846

Group type: EXPERIMENTAL
Intervention: Milvexian 60 mg
Number of subjects: 26
Study: 35263188

Group type: EXPERIMENTAL
Intervention: Extended Infusion Set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35263663

Group type: EXPERIMENTAL
Intervention: PPI consumption
Number of subjects: 156
Study: 35263691

Group type: EXPERIMENTAL
Intervention: Processed meat
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Replacement of processed meat with high-protein foods (unprocessed red meat, poultry, dairy products, fish, eggs, grains, nuts)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Total meat, unprocessed red meat, poultry, dairy products, eggs
Number of subjects: 688
Study: 35263963

Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: filgotinib 100 mg
Number of subjects: 109
Study: 35264105

Group type: EXPERIMENTAL
Intervention: ProMuscle (PM)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ProMuscle in Practice (PiP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: ProMuscle Implementation Pilots (IP)
Number of subjects: 148
Study: 35264144

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35264150

Group type: EXPERIMENTAL
Intervention: Biweekly SOX (oxaliplatin and S1, every 2 weeks)
Number of subjects: 42
Study: 35264246

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers identified through a 92-plex proteomic panel analysis.
Number of subjects: 406
Study: 35264340

Group type: EXPERIMENTAL
Intervention: Listening effort measured through the sentence-final word identification and recall (SWIR) test with single talker non-intelligible speech background noise and pupil dilation monitoring.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests for cognitive function evaluation.
Number of subjects: 30
Study: 35264341

Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Surgical treatments for AEDH (including craniotomy and DC)
Number of subjects: 2000
Study: 35264353

Group type: EXPERIMENTAL
Intervention: Healthy Life Centre programmes including physical activity offers and dietary courses
Number of subjects: 189

Group type: COMPARATOR
Intervention: Dropouts
Number of subjects: 189
Study: 35264400

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMCs) from patients who had a stroke
Number of subjects: 10

Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMCs) from controls
Number of subjects: 10
Study: 35264424

Group type: EXPERIMENTAL
Intervention: sNfL levels at preataxic stage (median 15.5 pg/mL [interquartile range 10.5-21.1 pg/mL])
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sNfL levels at ataxic stage (31.6 pg/mL [26.2-37.7 pg/mL])
Number of subjects: 40

Group type: COMPARATOR
Intervention: sNfL levels in controls (6.0 pg/mL [4.7-8.6 pg/mL])
Number of subjects: 40
Study: 35264434

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 4 mg/kg plus pembrolizumab 2 mg/kg every 2 weeks
Number of subjects: 33
Study: 35264559

Group type: EXPERIMENTAL
Intervention: ImmunoPET imaging using a radiolabeled HIV Env-specific broadly neutralizing antibody
Number of subjects: 0
Study: 35265135

Group type: EXPERIMENTAL
Intervention: PEEK retentive elements
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional nylon clip and metal housings
Number of subjects: 22
Study: 35265225

Group type: EXPERIMENTAL
Intervention: One-staged hybrid operation (embolization combined with microsurgical resection)
Number of subjects: 130
Study: 35265911

Group type: EXPERIMENTAL
Intervention: Fitbit devices for step count assessments; KardiaMobile for cardiac rhythm assessments; PROMs for pain and palpitations over 5 weeks.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Personal digital device and PROM data
Number of subjects: 59
Study: 35266046

Group type: EXPERIMENTAL
Intervention: Energy drink (240 mg caffeine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Coffee (240 mg caffeine)
Number of subjects: 16
Study: 35266059

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 56

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 56
Study: 35266065

Group type: EXPERIMENTAL
Intervention: Quantum Magnetic Resonance Therapy (QMRT)
Number of subjects: 5
Study: 35266132

Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CSF-CRP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serum CRP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serum PCT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CSF/blood glucose
Number of subjects: 48
Study: 35266172

Group type: EXPERIMENTAL
Intervention: 1064-nm laser device with a robotic arm
Number of subjects: 0
Study: 35266624

Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR-12) with direct-acting antiviral agents (DAAs)
Number of subjects: 385
Study: 35266655

Group type: EXPERIMENTAL
Intervention: Topical recombinant nerve growth factor (cenegermin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 35266773

Group type: EXPERIMENTAL
Intervention: Couple HOPES intervention
Number of subjects: 17
Study: 35266925

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pretransplant period factors (dialysis vintage, sclerostin, low bone volume at baseline)
Number of subjects: 69
Study: 35266926

Group type: EXPERIMENTAL
Intervention: LASSO models
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Artificial intelligence models
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: External validation of LASSO models
Number of subjects: 409

Group type: COMPARATOR
Intervention: Previously published models
Number of subjects: 409
Study: 35267093

Group type: EXPERIMENTAL
Intervention: 2D shear wave elastography (2D-SWE)
Number of subjects: 72
Study: 35267143

Group type: EXPERIMENTAL
Intervention: Reordered life priorities toward private life
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Stage III BC diagnosis
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Perceiving one's job as not very interesting
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Being an employee/clerk (vs. executive occupation)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Perceiving no support from the supervisor at baseline
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Perceiving negative interferences of cancer in daily life
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Perceiving a positive impact from experiencing cancer
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1097
Study: 35267254

Group type: EXPERIMENTAL
Intervention: Ketamine (single-session racemic ketamine treatments, administered intravenously)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of ketamine and psychotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Racemic ketamine, S-ketamine, or R-ketamine
Number of subjects: 9
Study: 35267535

Group type: EXPERIMENTAL
Intervention: Multitask learning of pre-/mid-treatment FDG-PET radiomics
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional clinical imaging
Number of subjects: 45

Group type: COMPARATOR
Intervention: FDG-PET delta radiomics
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multitask learning FDG-PET radiomics
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clinical imaging
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delta radiomics
Number of subjects: 45
Study: 35267579

Group type: EXPERIMENTAL
Intervention: 13.56 MHz modulated electro-hyperthermia (mEHT) boost during neoadjuvant treatment, twice a week during radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Whole pelvis radiotherapy of 40 Gy
Number of subjects: 60
Study: 35267593

Group type: EXPERIMENTAL
Intervention: Niraparib (from the PRIMA trial)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bevacizumab (from the PAOLA-1 trial)
Number of subjects: 12
Study: 35268280

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection with adjuvant erythritol air-polishing (FMDAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quadrant-wise debridement, scaling and root planing (Q-SRP)
Number of subjects: 40
Study: 35268456

Group type: EXPERIMENTAL
Intervention: EGD-first group
Number of subjects: 200
Study: 35268478

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg) administered 24 hours before surgery and on days 2, 3, 4, and 5 postoperatively.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo administered on the same schedule as colchicine.
Number of subjects: 101
Study: 35270262

Group type: EXPERIMENTAL
Intervention: CoVQuest-CC Questionnaire
Number of subjects: 0
Study: 35270339

Group type: EXPERIMENTAL
Intervention: Educational intervention concerning palliative care
Number of subjects: 37
Study: 35271541

Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS)
Number of subjects: 12006

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary resuscitation (CCPR)
Number of subjects: 12006
Study: 35271729

Group type: EXPERIMENTAL
Intervention: ß-d-N4-hydroxycytidine (NHC)
Number of subjects: 12
Study: 35272132

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m² administered intravenously)
Number of subjects: 25
Study: 35272392

Group type: EXPERIMENTAL
Intervention: Family-based clinical intervention
Number of subjects: 0
Study: 35272475

Group type: EXPERIMENTAL
Intervention: SENTINEL Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35272481

Group type: EXPERIMENTAL
Intervention: Skin biopsy detection of phosphorylated α-synuclein
Number of subjects: 0
Study: 35272506

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35272723

Group type: EXPERIMENTAL
Intervention: Healthy behaviour cluster (high physical activity and low consumption of sugary products)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Healthy behaviour cluster (high consumption of fruit and vegetables)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Unhealthy behaviour cluster (high sedentary behaviour and low consumption of fruit and vegetables)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Unhealthy behaviour cluster (smoking and alcohol consumption)
Number of subjects: 1391
Study: 35272771

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve replacement with the EVOQUE system
Number of subjects: 56
Study: 35272799

Group type: EXPERIMENTAL
Intervention: Active restoration of sinus rhythm (SR) through cardioversion and/or ablation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Absence/failure of restoration of sinus rhythm
Number of subjects: 117

Group type: COMPARATOR
Intervention: Spontaneous restoration of sinus rhythm
Number of subjects: 117
Study: 35272808

Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score (Score 1: acute MI size ≥19% LV, LVEF ≤47%, MVO >1.4% LV; Score 2: acute MI size ≥19% LV, LVEF ≤47%, IMH; Score 3: LVEF ≤45%, IMH)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score (Score 3: LVEF ≤45%, IMH)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score
Number of subjects: 604
Study: 35272845

Group type: EXPERIMENTAL
Intervention: Frailty assessment before surgery (defined as at least 1 positive test in physical, mental, and social domains).
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Frailty presence (29% in patients with adverse functional outcome).
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Mobility, nutrition, medication use, physical functioning, and self-rated health before surgery.
Number of subjects: 555
Study: 35272846

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in follicular fluid, cumulus cells, and endometrial samples
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fertilization rate, embryo developmental potential, and clinical outcome after frozen embryo transfer
Number of subjects: 16
Study: 35272946

Group type: EXPERIMENTAL
Intervention: Cancer drug repurposing for PIK3CA-driven overgrowth
Number of subjects: 0
Study: 35273012

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) initiated after <3 months to 8.3 years of developing pre-diabetes
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (participants who maintained normal fasting plasma glucose (FPG) and normal 2-hour plasma glucose (2hPG) levels during follow-up)
Number of subjects: 223
Study: 35273031

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exacerbation of COPD
Number of subjects: 0
Study: 35273055

Group type: EXPERIMENTAL
Intervention: Caller-attended telephone interviews (n=375)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Face-to-face surveys (n=205)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Both modalities (phone and face-to-face)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Phone surveys
Number of subjects: 580
Study: 35273988

Group type: EXPERIMENTAL
Intervention: Italian herb meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pumpkin spice meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 0
Study: 35274209

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion combined with intrathecal morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous wound infusion alone
Number of subjects: 0
Study: 35274279

Group type: EXPERIMENTAL
Intervention: Non-Black weight gain cluster
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Black weight loss cluster
Number of subjects: 283
Study: 35274386

Group type: EXPERIMENTAL
Intervention: Patient-owned fast-track protocols (PFTPs) during admission
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (no PFTP)
Number of subjects: 222
Study: 35274472

Group type: EXPERIMENTAL
Intervention: DNA methylation alterations in muscle of ICU patients
Number of subjects: 172
Study: 35274490

Group type: EXPERIMENTAL
Intervention: Chronic heart failure (CHF) patients
Number of subjects: 566

Group type: COMPARATOR
Intervention: Non-CHF patients (Control)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HFrEF patients
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: CHF patients (after multivariate adjustment)
Number of subjects: 566
Study: 35274704

Group type: EXPERIMENTAL
Intervention: EGFR TKIs (erlotinib, gefitinib, afatinib, or osimertinib)
Number of subjects: 246

Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: First-generation EGFR TKIs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Overall outcomes across mutation categories
Number of subjects: 246
Study: 35274717

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with capecitabine and oxaliplatin (CAPOX)
Number of subjects: 11
Study: 35274722

Group type: EXPERIMENTAL
Intervention: D-0316 (50 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: D-0316 (100 mg)
Number of subjects: 84
Study: 35275019

Group type: EXPERIMENTAL
Intervention: Dynamic gallium 68 imaging (details on dosage and duration not provided)
Number of subjects: 0
Study: 35275071

Group type: EXPERIMENTAL
Intervention: Design A (System Usability Scale)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Design B (System Usability Scale)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Design A (Normative path deviation)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Design B (Normative path deviation)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Design A (Effectiveness)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Design B (Effectiveness)
Number of subjects: 5
Study: 35275084

Group type: EXPERIMENTAL
Intervention: Online parenting intervention
Number of subjects: 334

Group type: COMPARATOR
Intervention: Staff-delivered parenting intervention
Number of subjects: 334
Study: 35275108

Group type: EXPERIMENTAL
Intervention: DEPITAC questionnaire administered by nurses
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: DEPITAC questionnaire
Number of subjects: 274
Study: 35275599

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in Fiebig 1 acute HIV infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) initiated in later Fiebig stages
Number of subjects: 0
Study: 35275706

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nivolumab with nivolumab/ipilimumab boosts
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nivolumab with nivolumab/ipilimumab boosts at week 8
Number of subjects: 86
Study: 35275734

Group type: EXPERIMENTAL
Intervention: Father-focused childhood obesity prevention program, details on dosage and duration not available
Number of subjects: 0
Study: 35275884

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF)
Number of subjects: 929
Study: 35276694

Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-kinase/PDGFRβ inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDAC inhibitors
Number of subjects: 0
Study: 35276889

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF) supplemented with two human milk oligosaccharides (HMO)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 194
Study: 35277288

Group type: EXPERIMENTAL
Intervention: Biparametric magnetic resonance imaging (bpMRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiparametric MRI
Number of subjects: 0